Congratulations to Apmonia Therapeutics and its CEO, Albin JEANNE, on the €10M fundraising, a major milestone marking the entry of TAX2 into first-in-human clinical development.
Apmonia Therapeutics is a biotech company developing innovative cancer immunotherapies targeting the tumor microenvironment, notably through TAX2, a peptide designed to target tumors overexpressing thrombospondin-1 (TSP-1).
At Angels Santé, we are proud to see our investors renew their trust and continue supporting the company in this new round, following an engagement that started at seed stage.
This long-term commitment reflects our strong belief in the quality of the team, the scientific robustness of the project, and its potential impact for patients.
A special thank you to our network administrator Stéphane Loze for his support and continued involvement alongside Apmonia Therapeutics.
Congratulations to the entire team on this key transition from preclinical to clinical development.
The journey ahead looks very promising 👏
𝗧𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗶𝘀 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗯𝗲𝗹𝗼𝘄 👇